Blockage of CTLA-4 via anti-CTLA-4- mAbs (e.g. ipilimumab and tremelimumab) is predicted to enhance T-cell activity against tumor cells and is under clinical trial for breast cancers (NCT02892734 and NCT02563925) [76]. The gene discussed is CTLA4; the disease is breast cancer.